** Non-GAAP adjustments include the following estimates: stock compensation expense of $17.7 million, intangible asset amortization of $6.4 million, termination costs of $1.6 million, and the associated tax impact from the aforementioned items. |
Silicon Laboratories Inc. | |||
Condensed Consolidated Balance Sheets | |||
(In thousands, except per share data) | |||
(Unaudited) | |||
| |||
| April 1, 2023 |
| December 31, 2022 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents | $ 716,377 |
| $ 499,915 |
Short-term investments | 435,699 |
| 692,024 |
Accounts receivable, net | 87,694 |
| 71,437 |
Inventories | 133,236 |
| 100,417 |
Prepaid expenses and other current assets | 87,734 |
| 97,570 |
Total current assets | 1,460,740 |
| 1,461,363 |
Property and equipment, net | 152,110 |
| 152,016 |
Goodwill | 376,389 |
| 376,389 |
Other intangible assets, net | 78,397 |
| 84,907 |
Other assets, net | 93,812 |
| 94,753 |
Total assets | $2,161,448 |
| $2,169,428 |
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable | $ 71,437 |
| $ 89,860 |
Current portion of convertible debt, net | 530,096 |
| -- |
Deferred revenue and returns liability | 11,258 |
| 6,780 |
Other current liabilities | 80,540 |
| 89,136 |
Total current liabilities | 693,331 |
| 185,776 |
Convertible debt, net | -- |
| 529,573 |
Other non-current liabilities | 48,663 |
| 49,071 |
Total liabilities | 741,994 |
| 764,420 |
Commitments and contingencies |
|
|
|
Stockholders' equity: |
|
|
|
Preferred stock – $0.0001 par value; 10,000 shares authorized; no shares issued | -- |
| -- |
Common stock – $0.0001 par value; 250,000 shares authorized; 31,997 and 31,994 shares issued and outstanding at April 1, 2023 and December 31, 2022, respectively | 3 |
| 3 |
Retained earnings | 1,425,914 |
| 1,415,693 |
Accumulated other comprehensive loss | (6,463) |
| (10,688) |
Total stockholders' equity | 1,419,454 |
| 1,405,008 |
Total liabilities and stockholders' equity | $2,161,448 |
| $2,169,428 |